NEW YORK (GenomeWeb) – DNA Script announced today that it has been awarded $5.5 million in grant funding from the European Commission and French investment bank Bpifrance.
DNA Script manufactures synthetic DNA and RNA using a proprietary enzymatic technology and nucleotide chemistry. Earlier this year, it acquired an exclusive license to a novel DNA building block for use in enzymatic DNA synthesis from Dynamic Combinatorial Chemistry.
According to Paris-based DNA Script, the grant money will be provided in the form of subsidies and refundable advances through the EC's Horizon 2020 European Innovation Council program and Bpifrance's innovation development programs.
"We are excited about recent breakthroughs we have made with our technology platform, and these additional resources will allow us to further accelerate the development of the company," DNA Script Cofounder and CEO Thomas Ybert said in a statement.
The grants follow a Series A financing round led by Illumina Ventures, in which DNA Script raised €11 million ($13.5 million). It said it has raised a total of $24 million to date.